Table 3.
Association between immune cell infiltration grade in tumors and clinicopathological parameters
| Low grade immune cell infiltrate (n = 183) | High grade immune cell infiltrate (n = 106) | r value | pvalue | |
|---|---|---|---|---|
| Age (≤50 / >50 years) | 36 (19.7) / 147 (80.3) | 24 (22.6) / 82 (77.4) | rφ = −0.035 | 0.549 |
| Invasive carcinoma (NST) / ILC / DCIS / Other invasive carcinomas | 130 (71.0) / 22 (12.0) / 16 (8.7) / 15 (8.2) | 77 (72.6) / 9 (8.5) / 17 (16.0) / 3 (2.8) | rs = −0.019 | 0.743 |
| DCIS status (Invasive DCIS − / Invasive DCIS +) | 61 (36.7) / 105 (63.3) | 31 (34.8) / 58 (65.2) | rφ = 0.019 | 0.761 |
| DCIS grade (1–2 / 3) | 62 (51.2) / 59 (48.8) | 15 (20.0) / 60 (80.0) | rφ = 0.311 | <0.01 |
| Estrogen receptor status (ER − / ER +) | 10 (6.1) / 154 (93.9) | 33 (37.1) / 56 (62.9) | rφ = −0.394 | <0.01 |
| Progesterone receptor status (PR − / PR +) | 20 (18.9) / 86 (81.1) | 38 (51.4) / 36 (48.6) | rφ = −0.342 | <0.01 |
| HER2 status (HER2 − / HER2 +) | 152 (92.1) / 13 (7.9) | 62 (69.7) / 27 (30.3) | rφ = 0.294 | <0.01 |
| Tumor size (≤20 / 21–50 / >50 mm) | 111 (66.9) / 47 (28.3) / 8 (4.8) | 47 (52.8) / 40 (44.9) / 2 (2.2) | rs = 0.122 | 0.052 |
| Tumor grade (I / II / III) | 72 (43.6) / 78 (47.3) / 15 (9.1) | 13 (14.6) / 42 (47.2) / 34 (38.2) | rs = 0.384 | <0.01 |
| Lymph node (− / +) | 140 (76.5) / 43 (23.5) | 63 (59.4) / 43 (40.6) | rφ = 0.180 | <0.01 |
| Involved lymph node (0 / 1–3 / >3) | 140 (76.5) / 33 (18.0) / 10 (5.5) | 63 (59.4) / 29 (27.4) / 14 (13.2) | rs = 0.187 | <0.01 |
Abbreviations: NST invasive carcinoma of no special type, ILC invasive lobular carcinoma, DCIS ductal carcinoma in situ, ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2, rs spearman rank order correlation, rφ phi coefficient. A small number of patients did not have complete data. Data presented as n (%).